PLUS THERAPEUTICS, INC. Logo

PLUS THERAPEUTICS, INC.

Develops targeted radiotherapeutics for difficult-to-treat cancers in adults and children.

PSTV | US

Overview

Corporate Details

ISIN(s):
US23283K2042 (+1 more)
LEI:
Country:
United States of America
Address:
4200 MARATHON BLVD., 78756 AUSTIN

Description

Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's technology platform is designed to deliver high-dose, localized radiation directly to tumors. Its core approach involves encapsulating Rhenium radioisotopes (186Re and 188Re) within nanoliposomes. The lead investigational drug, REYOBIQ™ (rhenium Re186 obisbemeda), is a nanoliposome therapy targeting brain and central nervous system (CNS) cancers, including recurrent glioblastoma and leptomeningeal metastases. A second pipeline program, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is a radioembolization therapy being developed for solid organ cancers, such as liver cancer. The use of Rhenium allows for both therapeutic beta radiation and gamma imaging during treatment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-17 08:35
8-K
English ZIP 65.6 KB
2025-11-05 09:30
4
English ZIP 7.1 KB
2025-10-30 17:20
10-Q
English ZIP 1.8 MB
2025-10-30 17:15
8-K
English ZIP 113.6 KB
2025-10-21 09:25
8-K
English ZIP 663.7 KB
2025-10-03 18:30
4
English ZIP 7.4 KB
2025-10-03 18:30
4/A
English ZIP 7.8 KB
2025-10-03 18:30
4
English ZIP 7.3 KB
2025-10-03 18:30
4/A
English ZIP 7.7 KB
2025-08-26 08:30
8-K
English ZIP 56.4 KB
2025-08-25 09:30
4
English ZIP 6.7 KB
2025-08-22 19:25
S-8
English ZIP 97.9 KB
2025-08-15 18:29
4
English ZIP 7.4 KB
2025-08-15 18:29
4
English ZIP 7.5 KB
2025-08-15 18:29
4
English ZIP 7.3 KB

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.